Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 11;9(5):50.
doi: 10.3390/cancers9050050.

Immunotherapy for Colorectal Cancer

Patrick M Boland  1 , Wen Wee Ma  2
Affiliations
Review

Immunotherapy for Colorectal Cancer

Patrick M Boland et al. Cancers (Basel). .

Erratum in

Abstract

The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.

Keywords: anti-PD1; colon cancer; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Patrick M. Boland has received research funding from Merck. Wen Wee Ma has no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988;319:525–532. doi: 10.1056/NEJM198809013190901. - DOI - PubMed
    1. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337. - PMC - PubMed
    1. Peeters M., Kafatos G., Taylor A., Gastanaga V.M., Oliner K.S., Hechmati G., Terwey J.H., van Krieken J.H. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur. J. Cancer. 2015;51:1704–1713. doi: 10.1016/j.ejca.2015.05.017. - DOI - PubMed
    1. Cremolini C., Loupakis F., Antoniotti C., Lupi C., Sensi E., Lonardi S., Mezi S., Tomasello G., Ronzoni M., Zaniboni A., et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–1315. doi: 10.1016/S1470-2045(15)00122-9. - DOI - PubMed
    1. Richman S.D., Southward K., Chambers P., Cross D., Barrett J., Hemmings G., Taylor M., Wood H., Hutchins G., Foster J.M., et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 2016;238:562–570. doi: 10.1002/path.4679. - DOI - PMC - PubMed